Cell therapy with standard chemo after surgery for stage IIIA lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether adding an experimental cell therapy (PANK-003) to standard chemotherapy after surgery can help prevent lung cancer from coming back. It is for people with stage IIIA non-small cell lung cancer who have already had surgery and are about to start or have just started adjuvant chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have stage IIIA non-small cell lung cancer (NSCLC) that was completely removed by surgery.
- You are scheduled to receive standard chemotherapy after surgery, and you have not had chemotherapy or radiation before surgery.
- Your cancer does not have certain genetic changes (EGFR or ALK) that are usually treated with targeted pills.
- You are generally healthy enough to be up and about (ECOG score 0 or 1).
- Your blood counts and liver/kidney function are within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at how lung tumors respond after chemotherapy given before surgery in people with stage IIIA non-small cell lung cancer (NSCLC). It may help doctors understand which past treatments lead to better results, since it uses medical records from approved clinical cases.
This trial tests an experimental NK cell therapy (PANK-003) given along with standard chemotherapy after surgery for solid tumors. The goal is to see if adding these immune cells can help prevent the cancer from coming back.
This trial tests combining chemotherapy with immunotherapy before surgery for people with stage III non-small cell lung cancer that has a PD-L1 level of 1% or higher. The goal is to see if this approach can improve outcomes.
This trial tests if LM103, given after surgery and standard chemotherapy, helps prevent non-small cell lung cancer from coming back. It is for people who have already had chemotherapy or immunotherapy before surgery and whose cancer did not return after surgery.
This trial tests a new approach for people with certain advanced non-small cell lung cancer (NSCLC) that has spread to lymph nodes in the chest but might still be removed. It combines a short course of high-precision radiation, immunotherapy (sintilimab), and standard chemotherapy before surgery to see if it can improve outcomes.
This trial tests whether giving a combination of two immunotherapy drugs with chemotherapy before surgery can help shrink stage III lung cancer and improve outcomes. It is for people whose cancer has spread to lymph nodes in the chest but can still be removed with surgery.
Hear when a new Stage IIIA Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.